Epratuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Epratuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD22
Clinical data
Trade names LymphoCide
Legal status
Legal status
  • Investigational
Identifiers
CAS Number 205923-57-5 N
ATC code none
PubChem SID 47206001
IUPHAR/BPS 8088
DrugBank DB04958 N
ChemSpider none
UNII 3062P60MH9 YesY
KEGG D04036 YesY
 NYesY (what is this?)  (verify)

Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).[1][2]

Clinical trials[edit]

A clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results.[3]

Results have been published for a phase II trial in untreated follicular lymphoma.[3]

Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging.[3][4]

The manufacturers in August 2009 announced success in early trials against SLE,[5] and started two Phase III clinical trials.
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.[6]

Mechanism of action[edit]

Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.

Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system"[6] via a process called trogocytosis.[3] (Other SLE therapies destroy B-cells which compromises the immune system.)

References[edit]